400898-77-3Relevant academic research and scientific papers
Preparation method of olatinib maleate
-
Paragraph 0023; 0050-0053; 0071-0073, (2020/11/23)
The invention discloses a preparation method of olatinib maleate. Trans-4-[(tert-butyloxycarbonyl) amino] cyclohexanecarboxylic acid and 4-chloro-7toluenesulfonyl-7Hpyrrolo-[2, 3-d] pyrimidine are used as starting materials, and the olatinib maleate is ob
BROAD-SPECTRUM CARBAPENEMS
-
Paragraph 00422, (2019/12/25)
The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.
Aminosulfonylmethylcyclohexanes as JAK inhibitors
-
Paragraph 0064, (2015/11/03)
The invention relates to a compound of formula wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.
PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS
-
Page/Page column 21, (2010/04/03)
Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds.
PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS
-
Page/Page column 55, (2008/06/13)
The invention relates to novel - at least 3,5-disubstituted - pyrazolo[1,5-a]pyrimidines of the formula (I), wherein the symbols R1 to R4 are as defined in the specification, tautomers thereof or N-oxides thereof, or (preferably phar
2,3-oxidosqualene-lanosterol cyclase inhibitors
-
, (2008/06/13)
The present invention relates to aminocyclohexanol derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.
